Evaxion Biotech A/S (EVAX) Prices 3M ADS IPO at $10/ADS
- Japan's Nikkei posts biggest point gain for fiscal year
- Citi downgrades tech stocks as its flagship indicator signals 'euphoria' levels
- UBS sees 5 warnings signals on semiconductor chip stocks
- 2 reasons why Tesla stock fell on Thursday
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
Evaxion Biotech Announces Pricing of Initial Public Offering
February 4, 2021 4:16 PM ESTCOPENHAGEN, Denmark, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Evaxion), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, today announced the pricing of its initial public offering of 3,000,000 American Depositary Shares (ADSs), at a public offering price of $10 per ADS, with each such ADS representing one ordinary share, DKK 1 nominal value per share, of Evaxion (Ordinary Shares). The gross proceeds from the offering are expected to be approximately $30 million before deducting underwriting fees and commissions and other offering expenses. Evaxion has granted the underwriters... More